These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30901950)

  • 1. Discovery of Small Molecules that Target Vascular Endothelial Growth Factor Receptor-2 Signalling Pathway Employing Molecular Modelling Studies.
    Rampogu S; Baek A; Park C; Parate S; Parameswaran S; Park Y; Shaik B; Kim JH; Park SJ; Lee KW
    Cells; 2019 Mar; 8(3):. PubMed ID: 30901950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.
    Rampogu S; Baek A; Zeb A; Lee KW
    BMC Cancer; 2018 Mar; 18(1):264. PubMed ID: 29514608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics-based insight of VEGFR-2 kinase domain: a combined study of pharmacophore modeling and molecular docking and dynamics.
    Parves MR; Riza YM; Alam S; Jaman S
    J Mol Model; 2022 Dec; 29(1):17. PubMed ID: 36550239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-ligand interaction-guided discovery of novel VEGFR-2 inhibitors.
    Zhang Y; Zhang M; Wang Y; Fan Y; Chen X; Yang Y; Hua Y; Xie W; Lu T; Tang W; Chen Y; Liu H
    J Biomol Struct Dyn; 2020 Jun; 38(9):2559-2574. PubMed ID: 31232191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Non-Peptidic Compounds against Chagas Disease Applying Pharmacophore Guided Molecular Modelling Approaches.
    Rampogu S; Lee G; Baek A; Son M; Park C; Zeb A; Yoon SH; Park S; Lee KW
    Molecules; 2018 Nov; 23(12):. PubMed ID: 30469538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent thieno[2,3-d]pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations.
    Elrazaz EZ; Serya RAT; Ismail NSM; Albohy A; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2021 Aug; 113():105019. PubMed ID: 34091286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of
    Ejaz SA; Aziz M; Fawzy Ramadan M; Fayyaz A; Bilal MS
    Molecules; 2023 May; 28(10):. PubMed ID: 37241785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
    Zengin M; Unsal Tan O; Arafa RK; Balkan A
    Bioorg Chem; 2022 Apr; 121():105696. PubMed ID: 35217379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
    Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
    J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
    Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
    Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.
    Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW
    J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
    Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
    Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy.
    Li J; Zhou N; Luo K; Zhang W; Li X; Wu C; Bao J
    Int J Mol Sci; 2014 Sep; 15(9):15994-6011. PubMed ID: 25216334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
    Bhojwani HR; Joshi UJ
    Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of promising B lymphocyte kinase inhibitors using structure-guided virtual screening.
    Yang S; Wahab S; Almoyad MAA; Chen Y; Kalam N; Khalid M
    J Biomol Struct Dyn; 2024 Aug; 42(13):7054-7064. PubMed ID: 37688373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.